Clinical trial
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or…
NCT00096005 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00096005 |
|---|---|
| Title | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
| Official title | A Phase I Trial Of 17-Allylaminogeldanamycin (17-AAG) And PS341 In Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and 48 more |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, bortezomib, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2010 |
| First posted | Nov 9, 2004 |
| Last update posted | Feb 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: